Latest & greatest articles for children

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on children or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on children and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for children

121. Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children

Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children - GOV.UK GOV.UK uses cookies to make the site simpler. Search Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children Provide clear information to patients and caregivers about how (...) on the patch packaging, the carton, and in the accompanying Patient Information Leaflet. To help you discuss this with patients, we have produced an updated ( ) Urgent medical attention should be sought for anyone accidentally exposed to a fentanyl patches. Administration of naloxone may help to reverse an opioid overdose. Storage and disposal of fentanyl patches Fentanyl patches should be stored out of sight and reach of children. After use, patches should be folded so that the adhesive side of the patch

MHRA Drug Safety Update2018

122. Burosumab for treating X-linked hypophosphataemia in children and young people

Burosumab for treating X-linked hypophosphataemia in children and young people Burosumab for treating X Burosumab for treating X-link -linked ed h hypophosphataemia in children and ypophosphataemia in children and y young people oung people Highly specialised technologies guidance Published: 10 October 2018 nice.org.uk/guidance/hst8 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) , to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights

National Institute for Health and Clinical Excellence - Highly specialised technology2018

123. APA Consensus Statement on updated fluid fasting guidelines for children prior to elective general anaesthesia

APA Consensus Statement on updated fluid fasting guidelines for children prior to elective general anaesthesia ‘We the undersigned representatives of our respective national societies agree that, based on the current convincing evidence base, unless there is a clear contra-indication, it is safe and recommended for all children able to take clear fluids*, to be allowed and encouraged to have them up to one hour before elective general anaesthesia’ Charles Stack, President, Association (...) of Paediatric Anaesthetists of Great Britain and Ireland Francis Veyckemans, President, European Society of Pediatric Anesthetists Anne Laffargue, Présidente, L’Association Des Anesthésistes-Réanimateurs Pédiatriques d’Expression Française

Association of Paediatric Anaesthetists of Great Britain and Ireland2018

124. Diagnosis and Management of Mild Traumatic Brain Injury in Children: A Systematic Review

Diagnosis and Management of Mild Traumatic Brain Injury in Children: A Systematic Review 30193325 2018 09 07 2168-6211 2018 Sep 04 JAMA pediatrics JAMA Pediatr Diagnosis and Management of Mild Traumatic Brain Injury in Children: A Systematic Review. e182847 10.1001/jamapediatrics.2018.2847 In recent years, there has been an exponential increase in the research guiding pediatric mild traumatic brain injury (mTBI) clinical management, in large part because of heightened concerns about (...) the consequences of mTBI, also known as concussion, in children. The CDC National Center for Injury Prevention and Control's (NCIPC) Board of Scientific Counselors (BSC), a federal advisory committee, established the Pediatric Mild TBI Guideline workgroup to complete this systematic review summarizing the first 25 years of literature in this field of study. To conduct a systematic review of the pediatric mTBI literature to serve as the foundation for an evidence-based guideline with clinical recommendations

EvidenceUpdates2018

125. Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children

Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children 30193284 2018 09 07 2168-6211 2018 Sep 04 JAMA pediatrics JAMA Pediatr Centers for Disease Control and Prevention Guideline on the Diagnosis and Management of Mild Traumatic Brain Injury Among Children. e182853 10.1001/jamapediatrics.2018.2853 Mild traumatic brain injury (mTBI), or concussion, in children is a rapidly growing public health concern because (...) epidemiologic data indicate a marked increase in the number of emergency department visits for mTBI over the past decade. However, no evidence-based clinical guidelines have been developed to date for diagnosing and managing pediatric mTBI in the United States. To provide a guideline based on a previous systematic review of the literature to obtain and assess evidence toward developing clinical recommendations for health care professionals related to the diagnosis, prognosis, and management/treatment

EvidenceUpdates2018

126. Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency

Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency 1 Recombinant IGF-1 Therapy in Children with Severe Primary IGF-1 Deficiency (SPIGFD) Formulated by the UK IGF-1 User’s Group February 2015. Revised February 2018 by Dr Helen Storr, Centre for Endocrinology, William Harvey Research Institute (WHRI), Charterhouse Square, Barts and the London School of Medicine, London EC1A 6BQ. Revision due: February 2021 Scope - To guide UK paediatric endocrinologists who are considering (...) signal transducer and activator of transcription 5B (STAT5B), IGF-1 and PAPP-A2 genes also lead to SPIGFD and short stature. In 2007, SPIGFD (defined as height <-3 SD, serum IGF-1 <2.5 th centile and normal GH) became a European Medicines Agency (EMA) licensed indication for recombinant human IGF-1 therapy (rhIGF-1) in the UK. B. Objective of rhIGF-1 treatment Improvement of adult height in SPIGFD children. C. Diagnosis of SPIGFD 1. Diagnosis of SPIGFD requires measurement of serum IGF-1

British Society for Paediatric Endocrinology and Diabetes2018

127. Effects of backward gait training on balance, gross motor function, and gait in children with cerebral palsy: a systematic review

Effects of backward gait training on balance, gross motor function, and gait in children with cerebral palsy: a systematic review 30043634 2018 07 25 1477-0873 2018 Jul 25 Clinical rehabilitation Clin Rehabil Effects of backward gait training on balance, gross motor function, and gait in children with cerebral palsy: a systematic review. 269215518790053 10.1177/0269215518790053 To investigate the effects of backward gait training on balance, gross motor function, and gait parameters in children (...) with cerebral palsy. PubMed, Cochrane Library, Web of Science, Science Direct, Physiotherapy Evidence Database (PEDro), and Google Scholar were searched up to May 2018. Randomized controlled trials were included if they involved any form of backward gait training for children with cerebral palsy. Two authors independently screened articles, extracted data and assessed the methodological quality using PEDro scale, with any confliction resolved by the third author. Modified Sackett Scale was used to determine

EvidenceUpdates2018

128. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group 30091945 2018 09 28 1527-7755 36 27 2018 Sep 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk (...) Rhabdomyosarcoma: A Report From the Children's Oncology Group. 2770-2777 10.1200/JCO.2018.77.9694 Purpose Intermediate-risk rhabdomyosarcoma (RMS) includes patients with either nonmetastatic, unresected embryonal RMS (ERMS) with an unfavorable primary site or nonmetastatic alveolar RMS (ARMS). The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

129. Long-Term Academic Functioning following Cogmed Working Memory Training for Children Born Extremely Preterm: A Randomized Controlled Trial

Long-Term Academic Functioning following Cogmed Working Memory Training for Children Born Extremely Preterm: A Randomized Controlled Trial 30177350 2018 09 04 1097-6833 2018 Aug 31 The Journal of pediatrics J. Pediatr. Long-Term Academic Functioning following Cogmed Working Memory Training for Children Born Extremely Preterm: A Randomized Controlled Trial. S0022-3476(18)30896-5 10.1016/j.jpeds.2018.07.003 To assess the effectiveness of Cogmed Working Memory Training compared with a placebo (...) program in improving academic functioning 24 months post-training in extremely preterm/extremely low birth weight 7-year-olds. A multicenter double-blind, placebo-controlled randomized controlled trial was conducted across all tertiary neonatal hospitals in the state of Victoria, Australia. Participants were 91 extremely preterm/extremely low birth weight 7-year-old children born in Victoria in 2005. Children were randomly assigned to either the Cogmed or placebo arm and completed the Cogmed

EvidenceUpdates2018

130. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children`s Oncology Group AALL0434 Methotrexate Randomization

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children`s Oncology Group AALL0434 Methotrexate Randomization 30138085 2018 10 05 1527-7755 36 29 2018 Oct 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate (...) Randomization. 2926-2934 10.1200/JCO.2018.77.7250 Early intensification with methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy. Two different approaches to MTX intensification exist but had not been compared in T-cell ALL (T-ALL): the Children's Oncology Group (COG) escalating dose intravenous MTX without leucovorin rescue plus pegaspargase escalating dose, Capizzi-style, intravenous MTX (C-MTX) regimen and the Berlin-Frankfurt-Muenster (BFM) high-dose intravenous MTX

EvidenceUpdates2018

131. Autism spectrum disorder: Warning signs, detection, diagnosis and assessment in children and adolescents

Autism spectrum disorder: Warning signs, detection, diagnosis and assessment in children and adolescents Haute Autorité de Santé - Trouble du spectre de l’autisme - Signes d’alerte, repérage, diagnostic et évaluation chez l’enfant et l’adolescent Développer la qualité dans le champ sanitaire, social et médico-social Recherche La HAS Accréditation & Certification Outils, Guides & Méthodes Recommandation de bonne pratique Trouble du spectre de l’autisme - Signes d’alerte, repérage, diagnostic et

HAS Guidelines2018

132. Vigabatrin (Kigabeq) - epilepsy in children between 1 month and 7 years of age

Vigabatrin (Kigabeq) - epilepsy in children between 1 month and 7 years of age Kigabeq | European Medicines Agency Search Search Menu Kigabeq vigabatrin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Kigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age. It is used in the following ways: on its own to treat infantile spasms (West syndrome), a rare epilepsy disorder that starts at a very young age, usually (...) KB) (PDF/39.52 KB) (PDF/39.4 KB) (PDF/39.4 KB) (PDF/36.88 KB) (PDF/36.88 KB) (PDF/13.59 KB) (PDF/13.59 KB) (PDF/36 KB) (PDF/36 KB) (PDF/21.52 KB) (PDF/21.52 KB) (PDF/37.23 KB) (PDF/37.23 KB) (PDF/34.84 KB) (PDF/34.84 KB) (PDF/35.27 KB) (PDF/35.27 KB) (PDF/21.77 KB) (PDF/21.77 KB) (PDF/21.26 KB) (PDF/21.26 KB) Pharmacotherapeutic group ANTIEPILEPTICS Therapeutic indication Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: Treatment in monotherapy

European Medicines Agency - EPARs2018

133. Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old)

Melatonin (Slenyto) - insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) Slenyto | European Medicines Agency Search Search Menu Slenyto melatonin Table of contents Authorised This medicine is authorised for use in the European Union. Overview Slenyto is a medicine for treating insomnia (difficulty sleeping) in children and adolescents (2 to 18 years old) who have: autism spectrum disorder (ASD), a range of conditions that affects the patient’s social interactions (...) ? Slenyto has been shown to be effective at improving sleeping time in children and adolescents with neurological conditions, including autism spectrum disorder and Smith-Magenis syndrome. In a main study of 125 patients, those given Slenyto over 13 weeks slept on average for 51 extra minutes of sleep a night compared with and 19 extra minutes for those given placebo (a dummy treatment). In addition, children who took Slenyto fell asleep around 38 minutes earlier than normal while those taking placebo

European Medicines Agency - EPARs2018

134. EPC Pilot Project: A Dual Approach To Facilitate Health Systems Uptake of Evidence Synthesis Reports. Anxiety in Children

EPC Pilot Project: A Dual Approach To Facilitate Health Systems Uptake of Evidence Synthesis Reports. Anxiety in Children Methods Research Report EPC Pilot Project: A Dual Approach To Facilitate Health Systems Uptake of Evidence Synthesis Reports. Anxiety in Children Methods Research Report EPC Pilot Project: A Dual Approach To Facilitate Health Systems Uptake of Evidence Synthesis Reports. Anxiety in Children Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health (...) and effective tools that can provide health systems with contextual and implementation information on the treatment of anxiety in children. • Lessons learned for EPC Program: Comparative effectiveness evidence syntheses often do not have sufficient information that allows decision-making and implementation of evidence. This includes information on costs, resources, patients’ values, acceptability and feasibility of interventions. Additional synthesis of study characteristics and intervention components

Effective Health Care Program (AHRQ)2018

135. Vaccine recommendations for children and youth for the 2018/2019 influenza season

Vaccine recommendations for children and youth for the 2018/2019 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. Keywords:   Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

Canadian Paediatric Society2018

136. Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents

Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies (...) with the greatest impact on clinical care. Looking for a change of scenery? Attend the ! . We want to hear from you! Complete our and get $30 off a print & online 2019 AAP Grand Rounds subscription! Diagnosis, Evaluation, and Management of High Blood Pressure in Children and Adolescents Carissa M. Baker-Smith , Susan K. Flinn , Joseph T. Flynn , David C. Kaelber , Douglas Blowey , Aaron E. Carroll , Stephen R. Daniels , Sarah D. de Ferranti , Janis M. Dionne , Bonita Falkner , Samuel S. Gidding , Celeste

American Academy of Pediatrics2018

137. Psychological therapies for the management of chronic and recurrent pain in children and adolescents.

Psychological therapies for the management of chronic and recurrent pain in children and adolescents. BACKGROUND: This is an update of the original Cochrane review first published in Issue 1, 2003, and previously updated in 2009, 2012 and 2014. Chronic pain, defined as pain that recurs or persists for more than three months, is common in childhood. Chronic pain can affect nearly every aspect of daily life and is associated with disability, anxiety, and depressive symptoms. OBJECTIVES: The aim (...) of this review was to update the published evidence on the efficacy of psychological treatments for chronic and recurrent pain in children and adolescents.The primary objective of this updated review was to determine any effect of psychological therapy on the clinical outcomes of pain intensity and disability for chronic and recurrent pain in children and adolescents compared with active treatment, waiting-list, or treatment-as-usual care.The secondary objective was to examine the impact of psychological

Cochrane2018

138. Appearance alteration of fruits and vegetables to increase their appeal to and consumption by school-age children: A pilot study

Appearance alteration of fruits and vegetables to increase their appeal to and consumption by school-age children: A pilot study 30275964 2018 11 14 2055-1029 5 2 2018 Jul-Dec Health psychology open Health Psychol Open Appearance alteration of fruits and vegetables to increase their appeal to and consumption by school-age children: A pilot study. 2055102918802679 10.1177/2055102918802679 Picky eating with regard to fruit and vegetables is common among children. This study investigated (...) the effectiveness of enhancing the visual appeal of fruit and vegetables to increase children's liking and consumption of fruit and vegetables. A pre-post experimental design was used, and the control and experimental groups were repeatedly exposed to the original food and transformed food, respectively, over 6 weeks. Significant differences in the consumption of pumpkin, sweet potato, spinach, carrot and aubergine were observed between the groups, demonstrating that the appearance appeal of fruit

Health psychology open2018 Full Text: Link to full Text with Trip Pro

139. Discoid lateral meniscus in children and adolescents: a histological study

Discoid lateral meniscus in children and adolescents: a histological study 30251229 2018 11 14 2197-1153 5 1 2018 Sep 24 Journal of experimental orthopaedics J Exp Orthop Discoid lateral meniscus in children and adolescents: a histological study. 39 10.1186/s40634-018-0153-5 Discoid lateral meniscus is the most frequent variant of the meniscus. Although the histology of normal menisci in children and in adults has been well described, few studies have focused on the histology of discoid menisci (...) . Furthermore, most of the patients in those studies were adults. The aim of the present study was to report the histological findings of discoid lateral meniscus in a group of children and adolescents, aged between 9 and 18, after arthroscopic partial resection, focusing on cellularity, arrangement of collagen fibers, and vascularity of the excised fragments. Furthermore, to report on MRI findings compared to the histological findings in the same region. Six patients (one female and five males) aged 9, 10

Journal of experimental orthopaedics2018 Full Text: Link to full Text with Trip Pro

140. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. BACKGROUND: Although amoxicillin-clavulanate is the recommended first-line empirical oral antibiotic treatment for non-severe exacerbations in children with bronchiectasis, azithromycin is also often prescribed for its convenient once-daily dosing. No randomised controlled trials involving acute (...) exacerbations in children with bronchiectasis have been published to our knowledge. We hypothesised that azithromycin is non-inferior to amoxicillin-clavulanate for resolving exacerbations in children with bronchiectasis. METHODS: We did this parallel-group, double-dummy, double-blind, non-inferiority randomised controlled trial in three Australian and one New Zealand hospital between April, 2012, and August, 2016. We enrolled children aged 1-19 years with radiographically proven bronchiectasis unrelated

Lancet2018